SLC5A2 and heart failure: The emergence of a diabetic pharmacotherapy, particularly the use of sodium-glucose cotransporter-2 inhibitors, as an effective approach in the management of heart failure across the spectrum of left ventricular ejection fraction highlights the need for their implementation in real-world clinical practice to reduce the burden of both diseases.